Thyroid Function Monitoring and Treatment Targets in Hyperthyroidism

Treatment Targets During Active Antithyroid Therapy

• Maintain free T4 at or slightly above the upper limit of the normal reference range throughout antithyroid drug therapy to ensure adequate hormone availability despite synthesis blockade. 1
• In pregnant patients, keep free T4 at or slightly above the non‑pregnant upper reference limit (or total T4 ≈ 1.5 × the non‑pregnant upper limit) to protect fetal thyroid development. 1
• Total T3 should be normalized, especially during the first 4–8 weeks of treatment, because T3 may stay elevated even after free T4 normalizes. (American College of Endocrinology & American Association of Clinical Endocrinologists) 2
• Use total T3 assays rather than free T3 assays for monitoring, as total T3 measurements have superior methodological reliability. 3
• TSH will remain suppressed (< 0.4 mU/L) for 1–3 months after free T4 and total T3 have normalized; this persistent suppression is expected and does not indicate treatment failure. (American College of Endocrinology & American Association of Clinical Endocrinologists) 2
• During the first several months after hyperthyroidism resolves, interpret TSH cautiously and only together with free T4 and total T3. (American College of Endocrinology & American Association of Clinical Endocrinologists) 2
• Do not aim for a normal TSH while antithyroid drugs are being used; attempting to normalize TSH can cause iatrogenic hypothyroidism. (American College of Endocrinology & American Association of Clinical Endocrinologists) 2

Monitoring Schedule

Initial Phase (first 1–2 months)

• Assess free T4 and total T3 1–2 months after initiating radioactive iodine or antithyroid drugs. (American College of Endocrinology & American Association of Clinical Endocrinologists) 2
• For patients on antithyroid drugs, measure free T4 (± total T3) at week 4 and adjust the methimazole dose accordingly. 1
• TSH is not useful in this early phase because it remains suppressed despite normalization of thyroid hormones. 1

Continuation Phase (until stable)

• If thyrotoxicosis persists, repeat biochemical monitoring every 4–6 weeks. (American College of Endocrinology & American Association of Clinical Endocrinologists) 2
• After euthyroidism is achieved on antithyroid drugs, check TSH and free T4 every 2–3 months. 1

Post‑Radioactive Iodine

• Repeat free T4 and total T3 every 1–2 months until stable results are obtained. (American College of Endocrinology) 4
• If hyperthyroidism persists at 3 months with minimal response, consider retreatment. (American College of Endocrinology & American Association of Clinical Endocrinologists) 2
• If hyperthyroidism persists beyond 6 months, retreatment with radioactive iodine is indicated. (American College of Endocrinology & American Association of Clinical Endocrinologists) 2

Long‑Term Follow‑Up

• Once euthyroidism or hypothyroidism is established, perform annual thyroid function testing for life. (American College of Endocrinology & American Association of Clinical Endocrinologists) 2

End‑of‑Treatment Considerations

• TSH must be fully normalized (within the laboratory reference range) before discontinuing a 12–18 month course of antithyroid drugs. 1
• Measure TSH‑receptor antibodies at therapy completion; elevated antibodies predict ≥ 50 % risk of relapse and may warrant continuation of medical therapy or definitive treatment. 1
• After stopping antithyroid drugs, monitor TSH and free T4 every 1–3 months for 6–12 months to detect early relapse. 1

Critical Pitfalls to Avoid

• Never rely on TSH alone for diagnosis or monitoring during the first 1–3 months of therapy; free T4 and total T3 are the primary parameters for dose adjustment. 1
• In patients with Graves’ ophthalmopathy, avoid iatrogenic hypothyroidism by keeping free T4 in the upper‑normal range to prevent worsening of eye disease. 1
• Do not order free T3 when TSH is normal; a normal TSH essentially excludes hyperthyroidism except in rare TSH‑producing pituitary adenoma or thyroid hormone resistance. 3
• When initiating thyroid hormone replacement after radioactive iodine, the required dose may be lower than typical full replacement; careful titration is necessary to avoid overt hypothyroidism. (American College of Endocrinology & American Association of Clinical Endocrinologists) 2